Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | CPS1 | P31327 | 2/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768007 | 0.89 | ABCB1 (0.43) | MEN1MAPTKMT2AWDR5 | |
| SCHEMBL7364226 | 0.85 | TP53 (0.42) | L3MBTL1ATMMRGPRX1POLBMEN1 | |
| SCHEMBL7363435 | 0.85 | DHODH (0.41) | L3MBTL1ATMMRGPRX1POLBMEN1 | |
| SCHEMBL6777480 | 0.84 | XDH (0.43) | POLBMEN1LMNAMAPTHTT | |
| SCHEMBL6767790 | 0.84 | NPC1 (0.48) | POLBMEN1LMNAMAPTHTT | |
| SCHEMBL6776660 | 0.84 | MAPT (0.40) | L3MBTL1ATMMRGPRX1POLBMEN1 | |
| SCHEMBL7397673 | 0.81 | POLB (0.40) | L3MBTL1ATMMRGPRX1POLBMEN1 | |
| SCHEMBL6772512 | 0.80 | LMNA (0.53) | L3MBTL1ATMMEN1LMNAHTT | |
| SCHEMBL7400004 | 0.79 | ROCK2 (0.45) | L3MBTL1ATMMRGPRX1POLBMEN1 | |
| SCHEMBL6770466 | 0.78 | MAPT (0.45) | MEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720339-B2 | SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2004-04-13 | — | — | US | claimed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | claimed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | claimed |
| EP-0888300-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | claimed |
| US-6720339-B2 | SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2002-12-26 | — | — | US | disclosed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | disclosed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | disclosed |
| EP-0888300-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | GABRA1, GABRA4, GABRA2 | L3MBTL1 433/4885ATM 1694/4885MRGPRX1 365/4885 |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | CNR1, HTR1A, GABRA6 | L3MBTL1 517/4885ATM 3065/4885MRGPRX1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.